On December 4, 2008, Sugita, Kazuyuki; Otsuka, Masaki; Oki, Hitoshi; Haginoya, Noriyasu; Ichikawa, Masanori; Ito, Masao published a patent.Safety of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate The title of the patent was Preparation of tricyclic compounds such as pyrrolobenzoxazepine derivatives and analogs thereof for treatment of hypercholesteremia, hyperlipemia, and arteriosclerosis. And the patent contained the following:
The title compounds [I; R1 = aryl or heteroaryl which may have 1 to 3 substituents; R2, R2a = H, halo, cyano, etc.; R3 = H, halo, alkyl, etc.; R4 = carboxyl, carboxycarbonyl, carboxyalkenyl, etc.; X = CH2, O, S; Y = N, CR3a; R3a = same as defined for R3; Z = N, CR3aa; R3aa = same as defined for R3; ring (N) = benzene or pyridine ring] are prepared I inhibit squalene synthetase and cholesterol synthesis. Thus, 2-(2-(2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-10-fluoro-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]ethyl)-2H-1,2,3,4-tetrazol-5-yl)acetic acid was prepared in a multistep process starting from 2-bromo-4-chloro-6-fluoroaniline and 2,5-dimethoxytetrahydrofuran. Compounds of this invention showed IC50 values of 0.56 nM to 7.6 nM against rat squalene synthetase. The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Safety of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate
The Article related to pyrrolobenzoxazepine derivative analog preparation hypercholesteremia hyperlipemia arteriosclerosis treatment, squalene synthetase cholesterol synthesis inhibitor pyrrolobenzoxazepine derivative analog preparation, tricyclic compound preparation hypercholesteremia hyperlipemia arteriosclerosis treatment and other aspects.Safety of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics